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OxytocinAbstract Background: Carbetocin is a long acting structural analog of human oxytocin and is
given as single IV bolus following the delivery; it is effective as an oxytocin infusion for several
hours because the latter has a very short duration of action which requires a continuous infusion
to achieve sustained uterotonic activity.
Multiple pregnancy is one of the most common causes of postpartum hemorrhage. This study was
done to compare the effect of carbetocin and oxytocin on uterine contraction and though the use of
other uterotonic drugs postoperative in multiple pregnancy patients undergoing elective C.S.
Patients and methods: Sixty patients were enrolled in this study, and they were classified randomly
into two groups: group C = received 100 lg carbetocin, group O = received 20 IU oxytocin. We
compared between the two groups as regard hemodynamic parameters (heart rate and mean arterial
blood pressure), uterine contraction, amount of blood loss and number of patients who needed to
reduce isoflurane concentration.
Results: As regards uterine contraction group O needed methylergometrine postoperative signifi-
cantly more than group C and as regards blood loss; it was significantly decreased more in group
C and though less reduction in blood pressure and less effect on heart rate than group O.
Conclusion: Single dose of carbetocin appears to be more effective than oxytocin for several hours
on uterine contraction and though preventing postpartum hemorrhage in multiple pregnancy
patients undergoing elective caesarian section.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Primary postpartum hemorrhage (PPH) is the most common
form of major obstetric hemorrhage. Definition of PPH is
118 N.G. Fahmy et al.the loss of 500 ml or more of blood from the genital tract
within 24 h of the delivery of baby [1].
Minor PPH (blood loss 500–1000 ml) and major PPH
(more than 1000 ml). Many patients known to be high risk
for developing PPH: twin pregnancy, known placenta previa,
placental abruption, obesity with BMI > 35; anemia < 9 g/dl,
previous PPH and age >40 years [2].
Almost 500,000 women die for this preventable cause each
year especially hemorrhage that occurred at time of delivery
[3].
Other nonfatal complications may occur as Sheehan’s syn-
drome (Pituitary infarction), coagulopathy, and organ damage
due to hypotension, shock, and risk of hysterectomy [4].
Uterine atony is the first cause of hemorrhage at time of
delivery; therefore, active management is better than expectant
management of the third stage of labor [5,6]. Third stage of
labor is that period following the delivery of baby till placental
delivery (see Fig. 1).
Uterotonic agents as oxytocin (10 IU) intramuscularly usu-
ally prevent PPH in low-risk vaginal and caesarian deliveries,
or intravenous infusion (20–40 IU in 1000 ml, 150 ml/h) which
is another alternative because of its short duration (its half-life
is approximately 3.5 min) [7,8].
Misoprostol (600 lg orally) is not effective when compared
with oxytocin in prevention of PPH, also carries increased
adverse effects which are dose related [9].
A long-acting oxytocin derivative, carbetocin, is licensed in
the UK specifically for the indication of prevention of PPH. It
is given as an IV bolus 100 lg over one minute.
Carbetocin is a synthetic oxytocin analog 1-deamino-1-
monocarbo (2-O-methyltyrosine) – oxytocin that binds to
oxytocin receptors with higher affinity. Oxytocin receptors
are G-protein coupled [10] and there mechanism of action
involves second messengers and the production of inositol
phosphate [11]. Each ampule contains 100 lg (0.1 mg) of
carbetocin (manufacture: Ferring Gmbh, Kiel, Germany)
(marketing authorization holder: Ferring Gmbh, Kiel,
Germany) (date of revision: June 2006). It is as effective as
oxytocin infusion with respect to blood loss following delivery
[12–14]. Its contractile effects of the uterus are apparent within
two min. and can be observed for approximately one hour [15].
It has half-life of 40 min (4–10 times longer than oxytocin). So
it is given as single IV bolus following the delivery of baby at60
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Figure 1 Heart rate values. Group C: Those patients who
received carbetocin. Group O: Those patients who received
oxytocin.elective or emergency cesarean section [16] and if further uter-
ine stimulation is needed, treatment with other uterotonic
drugs should be used. Carbetocin has also been shown to stim-
ulate milk letdown due to its action on oxytocin receptors on
the myoepithelial cells and there was not a significant amount
of it in breast milk [17]. Side effects are nausea, vomiting, chest
pain, tachycardia, hypotension and respiratory distress.
Contraindications do not use before delivery (it should not
be used to induce or augment labor since it could cause cardiac
or respiratory distress to mother or infant) [18] hypersensitivity
to carbetocin or oxytocin.
The aim of the present study was to compare the effect of
carbetocin versus oxytocin on the hemodynamics and the
effectiveness of uterine contraction and blood loss in twin
pregnancy patients undergoing elective C.S. under general
anesthesia using isoflurane and though it may contribute
carbetocin as substitute to oxytocin for elective C.S. at our
institution as well as others.
2. Patients and methods
After getting approval from hospital ethical committee and
written informed consent from patients, 60 twin pregnancy
patients ASA physical status I, aged 28–36 years, were sched-
uled for elective cesarean section in Ain Shams University
Hospital in the period between November 2012 and June
2013. Exclusion criteria included patients with hypertension,
pre-eclampsia, cardiac, respiratory, renal or liver disease,
pre-existing bleeding disorder such as hemophilia and women
taking therapeutic anticoagulants, hypersensitivity to carbe-
tocin or oxytocin. Patients with preoperative hemoglobin less
than 9.5 gm% and those who are pregnant with more than
two babies were also excluded from the study.
Pre-operative investigations in the form of ECG, complete
blood picture, coagulation profile, liver and kidney functions
were performed. A venous cannula 18G size was inserted
and basic monitoring (ECG, pulse oximeter, NIBP) was
applied. All patients underwent general anesthesia; pre-
oxygenation with 100% O2 for 4 min then induction with
intravenous thiopentone sodium 4–7 mg/kg, cisatracurium
0.5 mg/kg to facilitate endotracheal intubation (as all patients
underwent elective C.S. and were fasting for at least 8 h) and
anesthesia was maintained with oxygen (FiO2 0.4), isoflurane
(MAC 1) and intermittent doses of cisatracurium. Lactated
Ringer’s solution was infused at a rate of 10–15 ml/kg.
Patients were randomly allocated to lie into two equal
groups: group C (no = 30) received 100 lg carbetocin in
10 ml saline, and group O (no = 30) received 20 IU oxytocin
in 10 ml of saline solution. Randomization was performed by
using computer-generated program. Both drugs were prepared
preoperatively and coded so that the working investigator and
the obstetrician were blinded of the type of drug injected. The
uterotonic drug was injected slowly IV over one minute after
delivery of babies.
In all patients, the following parameters were recorded:
– hemodynamic parameters (heart rate and mean arterial
blood pressure),
– uterine contraction score; assessed by the obstetrician and
scored as very good (4), good (3), sufficient (2), poor (1)
or atony (0), and
Table 2 Mean heart rate values in two study groups.
Time (min) Group C (n= 30) Group O (n= 30) p value
0 (baseline) 76.2 ± 5.16 75.9 ± 4.9 0.83
HR 5 min 84.3 ± 3.1 83.1 ± 2.4 0.07
HR 10 min 83.3 ± 3.09 82.8 ± 2.7 0.058
HR 15 min 84.5 ± 2.74 84.1 ± 3 0.6
HR 20 min 81 ± 3.5 84.5 ± 3 0.08
HR 25 min 78.9 ± 3.1 84.8 ± 3* <0.001
HR 30 min 76.3 ± 1.8 82.5 ± 3.4* 0.023
HR 35 min 75.6 ± 2.8 80 ± 3.4* <0.001
HR 40 min 74.2 ± 3.1 80 ± 2* <0.001
HR 50 min 76.8 ± 3.6 79 ± 3* 0.03
HR 60 min 78.7 ± 2.8 79.4 ± 2.4 0.29
Group C: Those patients who received carbetocin.
Group O: Those patients who received oxytocin.
Values are expressed as mean ± SD.
* p< 0.05 was considered statistically significant between the 2
groups.
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swabs soaked with blood and also the amount of aspirated
blood).
If uterine contraction score was less than 3 after 5 min,
isoflurane concentration was decreased from 1 to 0.5. If still
unsatisfactory additional uterotonics were administered as
necessary (methylergometrine 100 IU). Patients who lost more
than 1200 ml of blood were prepared for blood transfusion to
maintain hemodynamic and good tissue perfusion.
We also recorded the number of patients who needed to
reduce MAC, those who needed additional uterotonics and
also the number of patients who had blood transfusion.
At the end muscle relaxation was reversed with 0.05 mg/kg
neostigmine and 0.02 mg/kg atropine.
PASS 11 was used for sample size calculation. Power calcu-
lations were based on former studies which revealed that in
order to detect a statistically significant difference between
the proportions of patients who require additional methergine
of 0.4 mg, a sample size of n= 26 per group was required. To
compensate for dropouts and missing data, the sample size was
increased to 30 patients per group. The test statistic used is the
two-sided Z test with pooled variance. The significance level of
the test was targeted at 0.05.
The statistical analysis was performed using a standard
SPSS software package version 17 (Chicago, IL). Data were
presented as mean values ± SD, numbers (%) or median
(IQR). Student’s t-test was used to analyze the parametric
data, and discrete (categorical) variables were analyzed using
the v2 test, non-parametric data were compared using
Mann–Whitney test, and p values < 0.05 were considered
statistically significant.
3. Results
60 twin pregnancy patients undergoing elective C.S. were suc-
cessfully enrolled in this study, 30 in each group; the variables
in demographic data did not show statistically significant dif-
ferences between the two groups with respect to age, body
mass index (BMI), preoperative hemoglobin concentration,
parity, hemoglobin, previous C.S., birth weight and duration
of anesthesia (Table 1).
Regarding hemodynamic variables, HR showed statistically
non-significant differences between the two groups till 20 minTable 1 Patient characteristics:
Group (C)
(n= 30)
Group (O)
(n= 30)
p-Value
Age (yr) 25.4 ± 4 24.5 ± 3 0.24
BMI (kg/m2) 25.6 ± 2.7 26 ± 2.8 0.6
Parity 3(2–4) 4(3–5) 0.07
Hemoglobin (gm%) 10 ± 0.9 9.8 ± 0.7 0.068
Previous C.S. 2(1–3) 2(2–2) 0.2
Duration of surgery (min) 33.8 ± 2.7 34 ± 3 0.79
Birth weight (kg) 2.4 ± 0.34 3 ± 0.3 0.2
Group C: Those patients who received carbetocin.
Group O: Those patients who received oxytocin.
Values are expressed as mean ± SD or median (IQR).
p> 0.05 was considered statistically nonsignificant.after injection of either carbetocin or oxytocin, but after
25 min till 50 min the differences between the two groups were
statistically significant: 78.9 ± 31 in group C, while it was 84.8
± 3 in group O after 25 min and (76.8 ± 3.6) and (79 ± 3)
respectively after 50 min; p value was < 0.05 till 60 min and
values returned to nonsignificant levels (Table 2).
On the other hand mean arterial blood pressure showed no
significant differences between the two groups till 15 min after
injection. Changes started to be significant after 20 min 75
± 2.6 in group C and 70 ± 3.8 in group O; till 50 min values
were 75 ± 4.7 in group C and 70 ± 3.7 in group O; p value
was < 0.05. Values returned to be nonsignificant after
60 min from injection as shown in Table 3.
There were significant differences between the two groups
as regards uterine contraction. Values were expressed as
median (range); uterine tone was evaluated 2 min and 2 h after
giving either carbetocin or oxytocin. In group C, for those who
received carbetocin it was [3] after 2 min and also [3] after 2 h
while in group O, for those who received oxytocin it was [2]
after 2 min and also after 2 h (p value < 0.001) (Table 4).
Regarding the number of patients who needed to reduce the
concentration of inhaled isoflurane from 1 to 0.5, there wereTable 3 Mean arterial blood pressure.
Time Group C (n= 30) Group O (n= 30) p value
Baseline
MABP
71 ± 6.3 72.1 ± 4.8 0.44
MABP 5 min 69.6 ± 3.6 70 ± 3.4 0.8
MABP 10 min 75.8 ± 2.7 74.3 ± 4 0.08
MABP 15 min 75.2 ± 2.8 71 ± 2.3 0.068
MABP 20 min 75 ± 2.6 70 ± 3.8* 0.003
MABP 25 min 74 ± 2.4 68.7 ± 3* 0.005
MABP 30 min 73.6 ± 2.4 68.8 ± 2.3* 0.004
MABP 35 min 73 ± 2.4 69.4 ± 5* 0.004
MABP 40 min 74 ± 1.8 69.3 ± 4.8* <0.001
MABP 50 min 75 ± 4.7 70.5 ± 3.7* 0.03
MABP 60 min 74.4 ± 5 70.6 ± 2.2 0.068
Group C: Those patients who received carbetocin.
Group O: Those patients who received oxytocin.
Data are presented as mean ± SD.
* p< 0.05 was considered statistically significant.
Table 4 Uterine contraction score.
Time Group C
(n= 30)
Group O
(n= 30)
p-Value
Uterine tone 2 min 3(2–3)* 2(1–2) <0.001
Uterine tone 2 h 3(2–3)* 2(2–3) <0.001
Group C: Those who received carbetocin.
Group O: Those who received oxytocin.
Values are expressed as median (range).
* p< 0.001 was considered statistically significant.
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patients (16.7%) needed to reduce isoflurane concentration
while in group O it was 15 patients (50%) (p value < 0.001).
Also the number of patients who needed methergine was 4
patients (13.3%) in group C while 15 patients (50%) in group
O needed one dose and 10 patients (33.3%) needed two doses
which means that it is statistically significant as p value
was < 0.001. Blood loss in group O patients (721 ± 50 ml)
was significantly higher than that in group C patients (437
± 45 ml) and so the percentage of patients who needed blood
transfusion in group O (13.3%) was significantly higher than
that in group C (3.33%) (Table 5).
4. Discussion
This study is one of the first studies done to compare carbe-
tocin with licensed dose of oxytocin. Its results demonstrated
an increased use of additional oxytocics with oxytocin group.
The reason for administering additional oxytocics was signifi-
cantly more liability to develop postpartum hemorrhage and
hence more blood loss.
Concerning oxytocin its cardiovascular effects include
hypotension, tachycardia and decrease in cardiac output. This
could be sufficient to cause significant compromise in high-risk
patients especially if given as rapid IV bolus injection; this
effect is markedly reduced if given with slower rate [19]. Some
suggest that the preservative, chlorobutanol, is the cause of
these hemodynamic changes [20].
Our results proved that hemodynamic variables; namely the
heart rate values showed statistically non-significant differ-
ences between the two groups till 20 min after injection of
either carbetocin or oxytocin but after 25 min till 50 min,
and the differences between both groups were statistically
significant. However, the mean arterial blood pressure values
showed non-significant differences between the two groups tillTable 5 Number of patients with unsatisfactory uterine tone.
Time G
Number of patients with reduced isoflurane concentration 5(
Number of patients who need methergine 4(
Number of patients who need blood transfusion 1(
Blood loss (ml) 43
Group C: Those who received carbetocin.
Group O: Those who received oxytocin.
Data are presented as number and percentage of patients or mean (SD).15 min after injection. Changes started to be significant after
20 min till 50 min.
A previous study done by Moertl and his co-workers in
2011, showed that patients treated with oxytocin had more
pronounced hypotension and hemodynamic rebound than
those received carbetocin [7].
Concerning uterine contraction and tonicity, our results
revealed a statistically significant better uterine contractility
in carbetocin group than oxytocin group both at 2 min and
2 h after injecting the test drug. Also the number of patients
who needed to reduce isoflurane concentration from 1% to
0.5% or additional methergine was significantly lower in the
carbetocin group.
Larciprete et al. in 2013 [4] showed that uterine contractility
was better in carbetocin group at 2, 12 and 24 h after C.S. In
agreement with our results, the study done by Borruto et al.
[21] 2009, revealed a lower rate of additional uterotonic need
in carbetocin group, and this conclusion agrees with many
other researches as those done by Su et al. in 2007 [6] and Bou-
cher et al. [14] who concluded that the use of carbetocin is
more effective than oxytocin for prevention of postpartum
hemorrhage after caesarian section. Dansereau et al., [22] also
described a lower additional oxytocics need for treatment of
uterine atony in those women who were treated with carbe-
tocin soon after delivery.
In this study, the amount of blood loss and also the need
for blood transfusion in oxytocin group patients were found
to be higher than those in patients who received carbetocin.
On the contrary, in 2013 Larciprette and his coworkers did
not demonstrate any difference in the amount of blood loss
after CS and in drop of hemoglobin level within 2 h and 24 h
between oxytocin and carbetocin groups [4].
As both carbetocin and oxytocin have more benign adverse
effect and hemodynamic profile than methylergometrine,
carbetocin became the drug of choice for those having
contraindications to methylergometrine; such as hypertensive
disorders, and cardiac problems. Cardiovascular disease is
listed in the cautions with the advice to avoid the use of carbe-
tocin in severe cardiovascular disease as the potent uterotonic
effect of carbetocin may shift a considerable blood volume to
the systemic circulation with subsequent fluid overload. How-
ever carbetocin would be preferable, as it reduces the use of
additional oxytocics and also reduces the incidence of PPH
as proved by Thomas et al. [23] who confirmed our results.
It is not known whether the carbetocin data from C.S. can
be extrapolated to vaginal birth or not. One randomized study
[14] of carbetocin versus oxytocin following vaginal birth
showed an increased rate of additional uterotonic interventionroup C (n= 30) Group O (n= 30) p-Value
16.7%) 15(50%) <0.001
13.3%) 15(50%) one dose <0.001
10(33.3%) 2 doses
3.33%) 4(13.3%) <0.001
7 ± 45 721 ± 50 <0.001
Comparative study between effect of carbetocin and oxytocin 121in the oxytocin group. The additional uterotonic drug indicates
a diagnosis of uterine atony which requires intensified moni-
toring and prolonged observation time in the postoperative
recovery area with an increased use of medical staff. The lesser
use of additional uterotonics after carbetocin found in this
study is an important outcome with possible financial savings.
Two studies have compared the cost effectiveness of prophy-
lactic carbetocin and oxytocin after C.S. In low risk patients
undergoing elective C.S., carbetocin was not cost saving [24].
In contrast, in those with risk factors for PPH, the mean cost
per woman was significantly lower following carbetocin treat-
ment compared with oxytocin one [25].
In conclusion, single dose of carbetocin appears to be more
effective than oxytocin with better uterine contraction, less
blood loss, less need for inhalational anesthetic reduction,
and more hemodynamic stability.
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